Mersine A Bryan1,2, Amy Tyler3, Chuan Zhou4,2, Derek J Williams5, David P Johnson5, Chén C Kenyon6, Heather Haq7, Tamara D Simon8, Rita Mangione-Smith9. 1. Department of Pediatrics, University of Washington, Seattle, Washington; mersine@uw.edu. 2. Seattle Children's Research Institute, Seattle, Washington. 3. Section of Hospital Medicine, Department of Pediatrics, School of Medicine, University of Colorado, Aurora, Colorado. 4. Department of Pediatrics, University of Washington, Seattle, Washington. 5. Division of Hospital Medicine, Monroe Carell Jr. Children's Hospital at Vanderbilt and Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, Tennessee. 6. Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia and Department of Pediatrics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 7. Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 8. Division of Hospital Medicine, Children's Hospital of Los Angeles, Los Angeles, California; and. 9. Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
Abstract
OBJECTIVES: To use adherence to the Pediatric Respiratory Illness Measurement System (PRIMES) indicators to evaluate the strength of associations for individual indicators with length of stay (LOS) and cost for bronchiolitis. METHODS: We prospectively enrolled children with bronchiolitis at 5 children's hospitals between July 1, 2014, and June 30, 2016. We examined associations between adherence to each individual PRIMES indicator for bronchiolitis and LOS and cost. Sixteen indicators were included, 9 "overuse" indicators for care that should not occur and 7 "underuse" indicators for care that should occur. We performed mixed effects linear regression to examine the association between adherence to each individual indicator and LOS (hours) and cost (dollars). All models controlled for patient demographics, patient complexity, and hospital. RESULTS: We enrolled 699 participants. The mean age was 8 months; 56% were male, 38% were white, and 63% had public insurance. Three indicators were significantly associated with shorter LOS and lower cost. All 3 indicators were overuse indicators and related to laboratory testing: no blood cultures (adjusted mean difference in LOS: -24.3 hours; adjusted mean cost difference: -$731, P < .001), no complete blood cell counts (LOS: -17.8 hours; cost: -$399, P < .05), and no respiratory syncytial virus testing (LOS: -16.6 hours; cost: -$272, P < .05). Two underuse indicators were associated with higher cost: documentation of oral intake at discharge ($671, P < .01) and documentation of hospital follow-up ($538, P < .05). CONCLUSIONS: A subset of PRIMES quality indicators for bronchiolitis are strongly associated with improved outcomes and can serve as important measures for future quality improvement efforts.
OBJECTIVES: To use adherence to the Pediatric Respiratory Illness Measurement System (PRIMES) indicators to evaluate the strength of associations for individual indicators with length of stay (LOS) and cost for bronchiolitis. METHODS: We prospectively enrolled children with bronchiolitis at 5 children's hospitals between July 1, 2014, and June 30, 2016. We examined associations between adherence to each individual PRIMES indicator for bronchiolitis and LOS and cost. Sixteen indicators were included, 9 "overuse" indicators for care that should not occur and 7 "underuse" indicators for care that should occur. We performed mixed effects linear regression to examine the association between adherence to each individual indicator and LOS (hours) and cost (dollars). All models controlled for patient demographics, patient complexity, and hospital. RESULTS: We enrolled 699 participants. The mean age was 8 months; 56% were male, 38% were white, and 63% had public insurance. Three indicators were significantly associated with shorter LOS and lower cost. All 3 indicators were overuse indicators and related to laboratory testing: no blood cultures (adjusted mean difference in LOS: -24.3 hours; adjusted mean cost difference: -$731, P < .001), no complete blood cell counts (LOS: -17.8 hours; cost: -$399, P < .05), and no respiratory syncytial virus testing (LOS: -16.6 hours; cost: -$272, P < .05). Two underuse indicators were associated with higher cost: documentation of oral intake at discharge ($671, P < .01) and documentation of hospital follow-up ($538, P < .05). CONCLUSIONS: A subset of PRIMES quality indicators for bronchiolitis are strongly associated with improved outcomes and can serve as important measures for future quality improvement efforts.
Authors: Ricardo A Quinonez; Matthew D Garber; Alan R Schroeder; Brian K Alverson; Wendy Nickel; Jenna Goldstein; Jeffrey S Bennett; Bryan R Fine; Timothy H Hartzog; Heather S McLean; Vineeta Mittal; Rita M Pappas; Jack M Percelay; Shannon C Phillips; Mark Shen; Shawn L Ralston Journal: J Hosp Med Date: 2013-08-19 Impact factor: 2.960
Authors: Shawn L Ralston; Matthew D Garber; Elizabeth Rice-Conboy; Grant M Mussman; Kristin A Shadman; Susan C Walley; Elizabeth Nichols Journal: Pediatrics Date: 2015-12-01 Impact factor: 7.124
Authors: Todd A Florin; Terri Byczkowski; Richard M Ruddy; Joseph J Zorc; Matthew Test; Samir S Shah Journal: J Pediatr Date: 2014-07-09 Impact factor: 4.406
Authors: Kohei Hasegawa; Yusuke Tsugawa; David F M Brown; Jonathan M Mansbach; Carlos A Camargo Journal: Pediatrics Date: 2013-06-03 Impact factor: 7.124
Authors: Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling Journal: Cochrane Database Syst Rev Date: 2013-06-04
Authors: Eric R Coon; Paul C Young; Ricardo A Quinonez; Daniel J Morgan; Sanket S Dhruva; Alan R Schroeder Journal: JAMA Pediatr Date: 2018-05-01 Impact factor: 16.193
Authors: Diana M Bowser; Katharine R Rowlands; Dhwani Hariharan; Raíssa M Gervasio; Lauren Buckley; Yara Halasa-Rappel; Elizabeth L Glaser; Christopher B Nelson; Donald S Shepard Journal: J Infect Dis Date: 2022-08-15 Impact factor: 7.759